Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Moderate Buy” from Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company.

Several analysts recently commented on ZLDPF shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock opened at $44.75 on Tuesday. The stock’s 50 day moving average is $47.93 and its 200 day moving average is $56.87. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The firm has a market cap of $3.20 billion, a P/E ratio of 3.32 and a beta of 0.86. Zealand Pharma A/S has a one year low of $35.93 and a one year high of $83.12.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. As a group, research analysts expect that Zealand Pharma A/S will post 2.37 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.